Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1080/17425247.2021.1886074 http://scihub22266oqcxt.onion/10.1080/17425247.2021.1886074 33632051!ä!33632051 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Expert+Opin+Drug+Deliv 2021 ; 18 (8): 1101-1115 Nephropedia Template TP {{tp|p=33632051|t=2021. Inhaled fixed-dose combination powders for the treatment of respiratory infections |pdf=|usr=}}{{33632051}} gab.com Text Inhaled fixed-dose combination powders for the treatment of respiratory infections JO: Expert Opin Drug Deliv http://www.kidney.de/pget.php?&tw=1&pmid=33632051 #FOAvip INTRODUCTION: Respiratory infections are a major cause of morbidity and mortality. As an alternative to systemic drug administration, inhaled drug delivery can produce high drug concentrations in the lung tissue to overcome resistant bacteria. The development of inhaled fixed-dose combination powders (I-FDCs) is promising next step in this field, as it would enable simultaneous drug-drug or drug-adjuvant delivery at the site of infection, thereby promoting synergistic activity and improving patient compliance. AREAS COVERED: This review covers the clinical and pharmaceutical rationales for the development of I-FDCs for the treatment of respiratory infections, relevant technologies for particle and powder generation, and obstacles which must be addressed to achieve regulatory approval. EXPERT OPINION: I-FDCs have been widely successful in the treatment of asthma and chronic obstructive pulmonary disease; however, application of I-FDCs towards the treatment of respiratory infections carries additional challenges related to the high dose requirements and physicochemical characteristics of anti-infective drugs. At present, co-spray drying is an especially promising approach for the development of composite fixed-dose anti-infective particles for inhalation. Though the majority of fixed-dose research has thus far focused on the combination of multiple antibiotics, future work may shift to the additional inclusion of immunomodulatory agents or repurposed non-antibiotics. Twit Text FOAVip Inhaled fixed-dose combination powders for the treatment of respiratory infections ????Expert Opin Drug Deliv http://www.kidney.de/pget.php?&tw=1&pmid=33632051 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33632051 #FOAvip English Wikipedia <ref>{{Cite pmid|33632051}}</ref> Inhaled fixed-dose combination powders for the treatment of respiratory infections #MMPMID33632051 Brunaugh AD; Sharma S; Smyth H Expert Opin Drug Deliv 2021[Aug]; 18 (8): 1101-1115 PMID33632051show ga INTRODUCTION: Respiratory infections are a major cause of morbidity and mortality. As an alternative to systemic drug administration, inhaled drug delivery can produce high drug concentrations in the lung tissue to overcome resistant bacteria. The development of inhaled fixed-dose combination powders (I-FDCs) is promising next step in this field, as it would enable simultaneous drug-drug or drug-adjuvant delivery at the site of infection, thereby promoting synergistic activity and improving patient compliance. AREAS COVERED: This review covers the clinical and pharmaceutical rationales for the development of I-FDCs for the treatment of respiratory infections, relevant technologies for particle and powder generation, and obstacles which must be addressed to achieve regulatory approval. EXPERT OPINION: I-FDCs have been widely successful in the treatment of asthma and chronic obstructive pulmonary disease; however, application of I-FDCs towards the treatment of respiratory infections carries additional challenges related to the high dose requirements and physicochemical characteristics of anti-infective drugs. At present, co-spray drying is an especially promising approach for the development of composite fixed-dose anti-infective particles for inhalation. Though the majority of fixed-dose research has thus far focused on the combination of multiple antibiotics, future work may shift to the additional inclusion of immunomodulatory agents or repurposed non-antibiotics. |*Dry Powder Inhalers[MESH] |*Respiratory Tract Infections/drug therapy[MESH] |Administration, Inhalation[MESH] |Aerosols[MESH] |Drug Delivery Systems[MESH] |Humans[MESH] |Particle Size[MESH]Inhaled fixed-dose combination powders for the treatment of respirator(epmc).pdf DeepDyve Pubget Overpricing